InflaRx (IFRX) Stock Forecast, Price Target & Predictions
IFRX Stock Forecast
InflaRx stock forecast is as follows: an average price target of $6.00 (represents a 287.10% upside from IFRX’s last price of $1.55) and a rating consensus of 'Strong Buy', based on 2 wall street analysts offering a 1-year stock forecast.
IFRX Price Target
The average price target for InflaRx (IFRX) is $6.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 287.10% upside from IFRX's last price of $1.55.
IFRX Analyst Ratings
According to 2 Wall Street analysts, InflaRx's rating consensus is 'Strong Buy'. The analyst rating breakdown for IFRX stock is 1 'Strong Buy' (50.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
InflaRx Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 06, 2023 | - | H.C. Wainwright | $6.00 | $2.92 | 105.48% | 287.10% |
The latest InflaRx stock forecast, released on Jan 06, 2023 by H.C. Wainwright company, set a price target of $6.00, which represents a 105.48% increase from the stock price at the time of the forecast ($2.92), and a 287.10% increase from IFRX last price ($1.55).
InflaRx Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.55 | $1.55 | $1.55 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of InflaRx stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to InflaRx's last price of $1.55. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 06, 2023 | Raymond James | Strong Buy | Strong Buy | Hold |
| Apr 05, 2023 | Guggenheim | - | Buy | Upgrade |
InflaRx's last stock rating was published by Raymond James on Apr 06, 2023. The company gave IFRX a "Strong Buy" rating, the same as its previous rate.
InflaRx Financial Forecast
InflaRx Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 22 | Dec 21 | Sep 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $390.62K | $199.54K | $129.88K | $346.83K | $130.37K | $79.74K | $60.63K | $1.27M | $1.28M | $2.40M | $220.00K | $5.30M | $5.17M | $124.37K | $18.74K |
| High Forecast | $390.62K | $199.54K | $129.88K | $346.83K | $130.37K | $159.49K | $62.53K | $1.32M | $1.31M | $2.40M | $220.00K | $5.30M | $5.17M | $124.37K | $18.74K |
| Low Forecast | $390.62K | $199.54K | $129.88K | $346.83K | $130.37K | $15.95K | $58.73K | $1.23M | $1.22M | $2.40M | $220.00K | $5.30M | $5.17M | $124.37K | $18.74K |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
InflaRx's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IFRX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
InflaRx EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 22 | Dec 21 | Sep 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-9.79M | $-14.55M | $-12.49M | $-6.68M | $-9.72M |
| Avg Forecast | $234.37K | $119.72K | $77.92K | $208.10K | $78.22K | $47.85K | $36.38K | $764.00K | $767.99K | $1.44M | $132.00K | $-13.14M | $3.10M | $74.62K | $-12.42M |
| High Forecast | $234.37K | $119.72K | $77.92K | $208.10K | $78.22K | $95.69K | $37.52K | $792.04K | $788.61K | $1.44M | $132.00K | $-10.52M | $3.10M | $74.62K | $-9.94M |
| Low Forecast | $234.37K | $119.72K | $77.92K | $208.10K | $78.22K | $9.57K | $35.24K | $735.96K | $731.91K | $1.44M | $132.00K | $-15.77M | $3.10M | $74.62K | $-14.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | -74.19% | 1.11% | -4.03% | -89.51% | 0.78% |
undefined analysts predict IFRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than InflaRx's previous annual EBITDA (undefined) of $NaN.
InflaRx Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 22 | Dec 21 | Sep 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-12.22M | $-13.27M | $-12.68M | $-6.86M | $-9.84M |
| Avg Forecast | $-15.53M | $-15.24M | $-14.94M | $-16.12M | $-13.63M | $-14.67M | $-11.61M | $-13.15M | $-10.78M | $-14.02M | $-15.84M | $-12.65M | $-12.99M | $-18.12M | $-10.99M |
| High Forecast | $-15.53M | $-15.24M | $-14.94M | $-16.12M | $-13.63M | $-14.13M | $-11.61M | $-13.15M | $-8.08M | $-14.02M | $-15.84M | $-10.12M | $-12.99M | $-18.12M | $-8.79M |
| Low Forecast | $-15.53M | $-15.24M | $-14.94M | $-16.12M | $-13.63M | $-14.67M | $-11.61M | $-13.15M | $-13.47M | $-14.02M | $-15.84M | $-15.18M | $-12.99M | $-18.12M | $-13.19M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.77% | 1.05% | 0.98% | 0.38% | 0.90% |
InflaRx's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IFRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
InflaRx SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 22 | Dec 21 | Sep 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $3.61M | $4.39M | $2.32M | $1.17M | $3.30M |
| Avg Forecast | $20.28M | $10.36M | $6.74M | $18.00M | $6.77M | $4.14M | $3.15M | $66.10M | $66.44M | $124.54M | $11.42M | $3.96M | $268.52M | $6.46M | $972.69K |
| High Forecast | $20.28M | $10.36M | $6.74M | $18.00M | $6.77M | $8.28M | $3.25M | $68.52M | $68.23M | $124.54M | $11.42M | $4.76M | $268.52M | $6.46M | $972.69K |
| Low Forecast | $20.28M | $10.36M | $6.74M | $18.00M | $6.77M | $827.86K | $3.05M | $63.67M | $63.32M | $124.54M | $11.42M | $3.17M | $268.52M | $6.46M | $972.69K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.32% | 1.11% | 0.01% | 0.18% | 3.39% |
InflaRx's average Quarter SG&A projection for Sep 23 is $124.54M, based on 1 Wall Street analysts, with a range of $124.54M to $124.54M. The forecast indicates a 3351.29% rise compared to IFRX last annual SG&A of $3.61M (Mar 23).
InflaRx EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 22 | Dec 21 | Sep 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.27 | $-0.30 | $-0.30 | $-0.25 | $-0.38 |
| Avg Forecast | $-0.26 | $-0.26 | $-0.25 | $-0.27 | $-0.23 | $-0.25 | $-0.20 | $-0.22 | $-0.18 | $-0.24 | $-0.27 | $-0.32 | $-0.22 | $-0.31 | $-0.52 |
| High Forecast | $-0.26 | $-0.26 | $-0.25 | $-0.27 | $-0.23 | $-0.24 | $-0.20 | $-0.22 | $-0.14 | $-0.24 | $-0.27 | $-0.32 | $-0.22 | $-0.31 | $-0.52 |
| Low Forecast | $-0.26 | $-0.26 | $-0.25 | $-0.27 | $-0.23 | $-0.25 | $-0.20 | $-0.22 | $-0.23 | $-0.24 | $-0.27 | $-0.32 | $-0.22 | $-0.31 | $-0.52 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.00% | 0.93% | 1.36% | 0.81% | 0.73% |
According to undefined Wall Street analysts, InflaRx's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IFRX previous annual EPS of $NaN (undefined).
InflaRx Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.82 | $17.50 | 2034.15% | Buy |
| PASG | Passage Bio | $0.60 | $6.00 | 900.00% | Buy |
| KRON | Kronos Bio | $0.93 | $7.63 | 720.43% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.28 | $10.00 | 681.25% | Buy |
| HOWL | Werewolf Therapeutics | $2.05 | $12.00 | 485.37% | Buy |
| SLS | SELLAS Life Sciences Group | $1.25 | $7.00 | 460.00% | Buy |
| IFRX | InflaRx | $1.55 | $6.00 | 287.10% | Strong Buy |
| INZY | Inozyme Pharma | $5.15 | $14.67 | 184.85% | Buy |
| FULC | Fulcrum Therapeutics | $3.55 | $9.86 | 177.75% | Buy |
| EYPT | EyePoint Pharmaceuticals | $11.15 | $30.00 | 169.06% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.66 | $7.00 | 163.16% | Buy |
| ERAS | Erasca | $2.80 | $7.00 | 150.00% | Buy |
| STOK | Stoke Therapeutics | $13.27 | $30.60 | 130.60% | Buy |
| CCCC | C4 Therapeutics | $6.41 | $13.50 | 110.61% | Buy |
| DSGN | Design Therapeutics | $6.02 | $9.67 | 60.63% | Buy |
| EWTX | Edgewise Therapeutics | $35.51 | $45.00 | 26.72% | Buy |
| IKNA | Ikena Oncology | $1.71 | $1.33 | -22.22% | Buy |
IFRX Forecast FAQ
Is InflaRx a good buy?
Yes, according to 2 Wall Street analysts, InflaRx (IFRX) is considered a 'Strong Buy'. The rating consensus is based on 1 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of IFRX's total ratings.
What is IFRX's price target?
InflaRx (IFRX) average price target is $6 with a range of $6 to $6, implying a 287.10% from its last price of $1.55. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will InflaRx stock go up soon?
According to Wall Street analysts' prediction for IFRX stock, the company can go up by 287.10% (from the last price of $1.55 to the average price target of $6), up by 287.10% based on the highest stock price target, and up by 287.10% based on the lowest stock price target.
Can InflaRx stock reach $2?
IFRX's average twelve months analyst stock price target of $6 supports the claim that InflaRx can reach $2 in the near future.
What are InflaRx's analysts' financial forecasts?
InflaRx's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.54M (high $1.67M, low $1.43M), average EBITDA is $926.45K (high $1M, low $858.99K), average net income is $-53.06M (high $-52.516M, low $-53.06M), average SG&A $80.15M (high $86.82M, low $74.32M), and average EPS is $-0.901 (high $-0.892, low $-0.901). IFRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.07M (high $1.07M, low $1.07M), average EBITDA is $640.12K (high $640.12K, low $640.12K), average net income is $-61.824M (high $-61.824M, low $-61.824M), average SG&A $55.38M (high $55.38M, low $55.38M), and average EPS is $-1.05 (high $-1.05, low $-1.05).